Analysts predict that Crispr Therapeutics AG (NASDAQ:CRSP) will report $59.43 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest sales estimate coming in at $76.70 million and the lowest estimate coming in at $14.30 million. Crispr Therapeutics posted sales of $120,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 49,425%. The company is scheduled to issue its next earnings results on Monday, February 24th.

According to Zacks, analysts expect that Crispr Therapeutics will report full-year sales of $272.00 million for the current fiscal year, with estimates ranging from $226.90 million to $289.27 million. For the next financial year, analysts expect that the company will post sales of $30.04 million, with estimates ranging from $2.03 million to $58.10 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. The business had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.

Several brokerages have recently weighed in on CRSP. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 23rd. Chardan Capital reaffirmed a “buy” rating and set a $72.50 target price on shares of Crispr Therapeutics in a research note on Monday, November 18th. Zacks Investment Research downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Goldman Sachs Group upped their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 19th. Finally, ValuEngine downgraded Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, January 3rd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have assigned a buy rating to the company. Crispr Therapeutics currently has a consensus rating of “Buy” and an average target price of $71.38.

In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $52.00, for a total value of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, President Rodger Novak sold 33,618 shares of the stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently modified their holdings of the business. Webster Bank N. A. acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $26,000. Perigon Wealth Management LLC acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $278,000. Farmers & Merchants Trust Co of Chambersburg PA acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $26,000. Millennium Management LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $4,366,000. Finally, Orbimed Advisors LLC acquired a new stake in shares of Crispr Therapeutics in the 3rd quarter worth $21,167,000. 49.82% of the stock is owned by institutional investors and hedge funds.

Shares of CRSP stock opened at $58.33 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32. The company has a market cap of $3.29 billion, a price-to-earnings ratio of -16.96 and a beta of 3.20. The stock has a 50 day simple moving average of $65.14 and a 200-day simple moving average of $52.14. Crispr Therapeutics has a 1-year low of $29.34 and a 1-year high of $74.00.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: How interest rates affect municipal bond prices

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link